Gene Therapy (2015) **22,** 286

www.nature.com/gt

## CORRIGENDUM

# Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs

C Chen, H Fang, Z Han, F Ye, T Ji, D Gong, F Li, J Zhou, D Ma and Q Gao

*Gene Therapy* (2015) **22,** 286; doi:10.1038/gt.2014.118

**Correction to:** *Gene Therapy* (2014) **21,** 975–983; doi:10.1038/gt.2014.79; published online 4 September 2014

Since the publication of this article the authors have noticed an error with regard to Figures 2e and g. The correct Figure 2 is reproduced here.

The authors apologize for any inconvenience caused.




**Figure 2.** Effects of Adv-TK, M7 and M8 on CMT-93 cells and non-cancerous cells *in vitro*. (**a**) CMT-93 cells were administered with increasing concentrations of GCV (0–600 μg ml$^{-1}$). Cell proliferation was assessed by MTT assay after 72 h. (**b**) CMT-93 cells were infected with various viral mutants at various MOI in the presence of 100 μg ml$^{-1}$ of GCV. Cell proliferation was assessed by MTT assay 72 h after infection. (**c**–**d**) Non-cancer cells, HUVEC and MCF-10A, were infected with various viral mutants at a MOI of 50 or 500 in the presence of 100 μg ml$^{-1}$ of GCV; transfect efficacy was determined 24 h after transfection of 500 MOI Adv-GFP, and cell proliferation was assessed by MTT assay 72 h after infection. (**e**) CMT-93 cells were infected with various viral mutants at a MOI of 2 or 50 in the presence of 100 μg ml$^{-1}$of GCV, apoptosis was assessed by flow cytometry 72 h after infection. (**f**) Non-cancer cells, HUVEC and MCF-10A, were infected with various viral mutants at a MOI of 50, apoptosis was assessed by flow cytometry 72 h after infection. (**g**) Representative flow cytometric analysis of the effects of Adv-TK, M7 and M8 administered in combination with 100 μg ml$^{-1}$ GCV in CMT-93 and MCF-10A cells. All the results were presented as the means of values obtained in three independent experiments.